skip to main content

Dyslipidemia Prevalence, Treatment, Control, and Awareness in the Canadian Health Measures Survey

Joffres, Michel ; Shields, Margot ; Tremblay, Mark ; Gorber, Sarah

Canadian Journal of Public Health, 2013, Vol.104(3), pp.e252-e257 [Periódico revisado por pares]

Texto completo disponível

Ver todas as versões
Citações Citado por
  • Título:
    Dyslipidemia Prevalence, Treatment, Control, and Awareness in the Canadian Health Measures Survey
  • Autor: Joffres, Michel ; Shields, Margot ; Tremblay, Mark ; Gorber, Sarah
  • Assuntos: Dyslipidemias ; population ; health surveys ; guidelines ; Canada
  • É parte de: Canadian Journal of Public Health, 2013, Vol.104(3), pp.e252-e257
  • Descrição: BACKGROUND: The most recent Canadian population-level data on lipid levels are from 1992. This study presents current estimates of Canadians with dyslipidemia, the proportion aware of their condition, and the proportion being treated and below target values. METHODS: The Canadian Health Measures Survey (2007-2009) assessed the prevalence, awareness and treatment of dyslipidemia. Dyslipidemia was defined as TC/HDL-C ratio [greater than or equal to] 5; measured LDL-C [greater than or equal to] 3.5 mmol/L; or taking lipid-modifying medications. The 2009 guidelines for the diagnosis and treatment of dyslipidemia were used to define low, moderate or high cardiovascular disease (CVD) risk and treatment initiation and targets. RESULTS: Forty-five percent of Canadians aged 18-79 years have dyslipidemia. Fifty-seven percent of respondents were not aware of their condition. Lipid-modifying therapy was initiated in individuals where treatment would be recommended in 49%, 20% and 54% of those at high, moderate, and low risk levels, respectively. The majority (81%) of those taking medication had their lipid levels under desirable levels, however, only 24% of those with dyslipidemia reported medication use. Overall, only 19% of those with dyslipidemia had their lipids under recommended levels. Only 41% of those taking lipid-modifying medication reached a recommended target of LDL-C <2 mmol/L or ApoB <0.8 g/L. CONCLUSION: There is still a high proportion of Canadians at high risk of CVD, with dyslipidemia, who are not being treated to recommended levels. These data need to be integrated into CVD reduction recommendations and represent an important baseline for assessing progress. KEY WORDS: Dyslipidemias; population; health surveys; guidelines; Canada CONTEXTE: Les plus recentes donnees en population sur les niveaux de lipides au Canada datent de 1992. Notre etude presente les estimations actuelles sur les Canadiens ayant une dyslipidemie, la proportion de gens connaissant leur etat et la proportion traitee pour une dyslipidemie, mais presentant des valeurs sous-optimales. METHODE: L'Enquete canadienne sur les mesures de la sante (20072009) a evalue la prevalence, la connaissance et le traitement des dyslipidemies. Une dyslipidemie etait definie ainsi: ratio CT/HDLc [mayor que o igual a] 5; LDLc mesure [mayor que o igual a] 3,5 mmol/L; ou prise de medicaments hypolipemiants. Nous avons utilise les directives de 2009 pour le diagnostic et le traitement des dyslipidemies pour definir le risque de maladie cardiovasculaire (MCV)--faible, modere ou eleve--ainsi que l'instauration du traitement et les valeurs cibles du traitement. RESULTATS: Quarante-cinq p. cent des Canadiens de 18 a 79 ans ont une dyslipidemie. Cinquante-sept p. cent des repondants n'etaient pas conscients de leur etat. Des traitements hypolipemiants avaient ete instaures, dans les cas ou ces traitements etaient recommandes, chez 49 %, 20 % et 54 % respectivement des sujets presentant un niveau de risque eleve, modere et faible. La majorite (81 %) des sujets prenant des medicaments avaient des niveaux de lipides sous-optimaux, mais seulement 24 % des sujets ayant une dyslipidemie disaient prendre des medicaments. Globalement, seulement 19 % des sujets ayant une dyslipidemie avaient des niveaux de lipides sous les niveaux recommandes. Seulement 41 % des sujets prenant des hypolipemiants atteignaient la cible recommandee (LDLc <2 mmol/L ou Apo B <0,8 g/L). CONCLUSION: Il y a encore une proportion elevee de Canadiens presentant un risque eleve de MCV, avec dyslipidemie, qui ne sont pas traites selon les niveaux recommandes. Ces donnees devraient etre integrees dans les recommandations sur la reduction des MCV; elles representent aussi une importante base de reference pour evaluer les progres. MOTS CLES: dyslipidemies; population; enquetes de sante; directives; Canada
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.